Lv22
105 积分 2021-04-26 加入
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
1小时前
待确认
Safety considerations for cereblon-recruiting targeted protein degraders
1小时前
已完结
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
22小时前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
3天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
4天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
4天前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
14天前
已完结
Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer
1个月前
已完结
A renaissance in targeting the PI3K/AKT/mTOR pathway
1个月前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
1个月前
已完结
皖公网安备34019202002308
